Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label rollover extension of iptacopan in adults with primary IgA nephropathy
2023-508690-92-00Phase 4Authorised
- Sponsor
- Novartis
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 34
01
Overview
Phase 4, open-label, single-arm trial of Iptacopan in IgA nephropathy (IgAN), sponsored by Novartis. Primary endpoint: Safety and tolerability. Planned start May 2024; status: authorised.
02
Drugs
Iptacopan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2023-508690-92-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508690-92-00.